Statistiche di base
| LEI | 969500PVBQFWQKVDMD80 |
| CIK | 1613780 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to DBV Technologies S.A. - Depositary Receipt (Common Stock)
SEC Filings (Chronological Order)
Questa pagina fornisce un elenco completo e cronologico dei depositi SEC, esclusi i documenti di proprietà che forniamo altrove.
| June 5, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 3, 2026 Date of Report (Date of earliest event reported) DBV Technologies S.A. (Exact name of registrant as specified in its charter) France 001-36697 Not applicable (State or other jurisdiction of incorporation) (Commission Fil |
|
| June 4, 2026 |
Table 1: Newly Registered Securities Calculation of Filing Fee Tables S-8 DBV Technologies S.A. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Ordinary Shares, nominal value euro0.10 per share reserved for future issuance upon the exercise of stock optio |
|
| June 4, 2026 |
As filed with the Securities and Exchange Commission on June 4, 2026 S-8 As filed with the Securities and Exchange Commission on June 4, 2026 Registration No. |
|
| June 4, 2026 |
DBV TECHNOLOGIES PLAN RULES OF THE 2026 STOCK OPTION PLAN (INTERNATIONAL VERSION) EX-99.1 Exhibit 99.1 DBV TECHNOLOGIES PLAN RULES OF THE 2026 STOCK OPTION PLAN (INTERNATIONAL VERSION) Purpose and background of the Plan: The Annual General Meeting of Shareholders of DBV Technologies (“DBV Technologies” or the “Company”) held on June 3, 2026 (the “2025 AGM”), in its 36th resolution, authorized the board of directors of the Company (the “Board of Directors”) to grant options to p |
|
| June 4, 2026 |
DBV TECHNOLOGIES PLAN RULES FOR THE 2026 FREE SHARE PLAN (INTERNATIONAL VERSION) EX-99.2 Exhibit 99.2 DBV TECHNOLOGIES PLAN RULES FOR THE 2026 FREE SHARE PLAN (INTERNATIONAL VERSION) Purpose and background of the Plan: The Annual General Meeting of Shareholders of DBV Technologies (“DBV Technologies” or the “Company”) held on June 3, 2026, in its 35th resolution, authorized the board of directors of the Company (the “Board of Directors”) to grant free shares (such grants being |
|
| June 4, 2026 |
DBV TECHNOLOGIES PLAN RULES FOR THE 2026 PERFORMANCE SHARE UNIT PLAN GRANT DATE JUNE 5, 2026 EX-99.3 Exhibit 99.3 DBV TECHNOLOGIES PLAN RULES FOR THE CEO 2026 PERFORMANCE SHARE UNIT PLAN GRANT DATE JUNE 5, 2026 Purpose and background of the Plan: DBV Technologies (“DBV Technologies” or the “Company”) is granting to its Chief Executive Officer (the “Participant”) conditional rights to receive shares of DBV Technologies for free under this 2026 Performance Share Unit Plan (the “Plan”). The |
|
| June 3, 2026 |
EX-3.1 Exhibit 3.1 BY-LAWS (Updated by decision of the General Meeting of Shareholders on June 3, 2026) DBV Technologies Limited Company with share capital of €29,606,149.70 107, avenue de la République - 92320 Châtillon, France Nanterre Trade and Companies Register No. 441 772 522 1 I. - CHARACTERISTIC FEATURES OF THE COMPANY Article 1 - Form The Company was incorporated in the form of a French L |
|
| June 3, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 3, 2026 Date of Report (Date of earliest event reported) DBV Technologies S.A. (Exact name of registrant as specified in its charter) France 001-36697 Not applicable (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 11, 2026 |
DBVTechnologies S.A. 2025AnnualReport toSecurityholders UNITEDSTATES SECURITIESANDEXCHANGECOMMISSION Washington,D.C.20549 FORM10-K (MarkOne) ANNUALREPORTPURSUANTTOSECTION13OR15(d)OFTHESECURITIESEXCHANGEACTOF1934 ForthefiscalyearendedDecember31,2025 or [ TRANSITIONREPORTPURSUANTTOSECTION13OR15(d)OFTHESECURITIESEXCHANGEACTOF1934 Forthetransitionperiodfromto Commissionfilenumber001-36697 DBVTECHNOL |
|
| May 11, 2026 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi |
|
| May 5, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 30, 2026 Date of Report (Date of earliest event reported) DBV Technologies S.A. (Exact name of registrant as specified in its charter) France 001-36697 Not applicable (State or other jurisdiction of incorporation) (Commission F |
|
| May 4, 2026 |
Table 1: Newly Registered Securities Calculation of Filing Fee Tables S-8 DBV Technologies S.A. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Ordinary Shares, nominal value Euro0.10 per share reserved for future issuance upon the exercise of stock optio |
|
| May 4, 2026 |
As filed with the Securities and Exchange Commission on May 4, 2026 S-8 As filed with the Securities and Exchange Commission on May 4, 2026 Registration No. |
|
| May 4, 2026 |
DBV TECHNOLOGIES PLAN RULES FOR THE 2026 PERFORMANCE SHARE UNIT PLAN GRANT DATE MAY 5, 2026 EX-99.1 Exhibit 99.1 DBV TECHNOLOGIES PLAN RULES FOR THE CEO 2026 PERFORMANCE SHARE UNIT PLAN GRANT DATE MAY 5, 2026 Purpose and background of the Plan: DBV Technologies (“DBV Technologies” or the “Company”) is granting to its Chief Executive Officer (the “Participant”) conditional rights to receive shares of DBV Technologies for free under this 2026 Performance Share Unit Plan (the “Plan”). The r |
|
| May 1, 2026 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defi |
|
| April 30, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36697 DBV TECHNO |
|
| April 30, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 30, 2026 Date of Report (Date of earliest event reported) DBV Technologies S.A. (Exact name of registrant as specified in its charter) France 001-36697 Not applicable (State or other jurisdiction of incorporation) (Commission F |
|
| April 30, 2026 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to |
|
| April 30, 2026 |
Châtillon, France, April 30, 2026 EX-99.1 Exhibit 99.1 Press Release Châtillon, France, April 30, 2026 DBV Technologies Reports First Quarter 2026 Financial Results • Reported cash and cash equivalents of $229 million as of March 31, 2026 —providing funding into the second quarter of 2027 following the full exercise of the ABSA Warrants and BS Warrants issued in its March 2025 private placement (“PIPE”) financing • Continued disci |
|
| April 30, 2026 |
DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 EX-4.5 Exhibit 4.5 DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description of the ordinary shares, the American Depositary Shares and the by-laws of DBV Technologies S.A. (“DBV” or the “Company”) is a summary and does not purport to be complete. This summary is subject to, and qualified in its entirety by reference to, the comple |
|
| March 26, 2026 |
DBV Technologies Reports Full Year 2025 Financial Results and Business Update EX-99.1 Exhibit 99.1 DBV Technologies Reports Full Year 2025 Financial Results and Business Update • Continued advancing the VIASKIN® Peanut Patch clinical development programs in peanut-allergic toddlers (1 through 3 years old) and children (4 through 7 years old) • Bolstered executive leadership team in preparation for BLA submission and potential approval • Reported cash and cash equivalents of |
|
| March 26, 2026 |
agreementktrapp |
|
| March 26, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 26, 2026 Date of Report (Date of earliest event reported) DBV Technologies S.A. (Exact name of registrant as specified in its charter) France 001-36697 Not applicable (State or other jurisdiction of incorporation) (Commission F |
|
| March 26, 2026 |
bylaws 1 BY-LAWS (Updated by decision of the CEO on March 12th, 2026) DBV Technologies Limited Company with share capital of €29,604,244. |
|
| March 26, 2026 | ||
| March 26, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 or □ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36697 DBV TECHNOLOGIE |
|
| March 2, 2026 |
EX-99.1 Exhibit 99.1 DBV Technologies Highlights Additional Data from Successful Phase 3 VITESSE Study at the AAAAI 2026 Annual Meeting • Approximately 83% of children treated with the VIASKIN® Peanut Patch increased their eliciting dose at month 12, compared to approximately 48% in the placebo group • Approximately 60% of children treated with the VIASKIN® Peanut Patch increased their eliciting d |
|
| March 2, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 28, 2026 Date of Report (Date of earliest event reported) DBV Technologies S.A. (Exact name of registrant as specified in its charter) France 001-36697 Not applicable (State or other jurisdiction of incorporation) (Commissio |
|
| January 20, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 16, 2026 Date of Report (Date of earliest event reported) DBV Technologies S.A. (Exact name of registrant as specified in its charter) France 001-36697 Not applicable (State or other jurisdiction of incorporation) (Commission |
|
| January 20, 2026 |
Number of shares and voting rights EX-99.1 Exhibit 99.1 DBV Technologies Announces €166.7 Million in Gross Proceeds Following the Full Exercise of the ABSA Warrants and BS Warrants Issued on its March 2025 Financing The Company is sufficiently funded to support operations and commercial preparedness, including infrastructure buildup, to launch the VIASKIN® Peanut patch in children 4 to 7 years old in the U.S., if approved. DBV Tech |
|
| December 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 16, 2025 Date of Report (Date of earliest event reported) DBV Technologies S.A. (Exact name of registrant as specified in its charter) France 001-36697 Not applicable (State or other jurisdiction of incorporation) (Commissio |
|
| December 16, 2025 |
Châtillon, France, December 16, 2025 EX-99.1 Exhibit 99.1 Châtillon, France, December 16, 2025 DBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years • VITESSE met its primary endpoint: the lower bound of the 95% confidence interval (CI) of the difference between treatment arms was 24.5%, exceeding the prespecified threshold of 15% • 46.6% of |
|
| October 30, 2025 |
DBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board of Directors EX-99.1 Exhibit 99.1 DBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board of Directors DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Market: DBVT), (the “Company” or “DBV”), a clinical-stage biopharmaceutical company, today announced the provisional appointment of a new independent director, Dr. Philina Lee, to its Board of Directors (the “Board”), effective Octobe |
|
| October 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 30, 2025 Date of Report (Date of earliest event reported) DBV Technologies S.A. (Exact name of registrant as specified in its charter) France 001-36697 Not applicable (State or other jurisdiction of incorporation) (Commission |
|
| October 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 28, 2025 Date of Report (Date of earliest event reported) DBV Technologies S.A. (Exact name of registrant as specified in its charter) France 001-36697 Not applicable (State or other jurisdiction of incorporation) (Commission |
|
| October 29, 2025 |
nine months ended September 30, EX-99.1 Exhibit 99.1 DBV Technologies Reports Third Quarter 2025 Financial Results • DBV closes Q3 2025 with a cash and cash equivalents balance of $69.8 million, taking cash runway into the third quarter of 2026 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a clinical-stage biopharmaceutical company (the “Company”), reported financi |
|
| October 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36697 DBV TE |
|
| September 18, 2025 |
DBV Technologies Announces Resignation of Board Member EX-99.1 Exhibit 99.1 DBV Technologies Announces Resignation of Board Member DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Market: DBVT), (the “Company” or “DBV”), a clinical-stage biopharmaceutical company, today announced the resignation of Daniel Soland, as a member of its Board of Directors (the “Board”), effective immediately. “On behalf of the Board, DBV’s management team and |
|
| September 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 18, 2025 Date of Report (Date of earliest event reported) DBV Technologies S.A. (Exact name of registrant as specified in its charter) France 001-36697 Not applicable (State or other jurisdiction of incorporation) (Commissi |
|
| September 5, 2025 |
Châtillon, France, September 5, 2025 EX-99.1 Exhibit 99.1 Châtillon, France, September 5, 2025 DBV Technologies Establishes an At-The-Market (ATM) Program on Nasdaq DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Capital Market: DBVT) (the “Company”), a clinical-stage biopharmaceutical company, today announced that it has filed a prospectus supplement with the U.S. Securities and Exchange Commission (“SEC”) relating to |
|
| September 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 5, 2025 Date of Report (Date of earliest event reported) DBV Technologies S.A. (Exact name of registrant as specified in its charter) France 001-36697 Not applicable (State or other jurisdiction of incorporation) (Commissio |
|
| September 5, 2025 |
Up to $150,000,000 of Ordinary Shares American Depositary Shares 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration Statement File No. |
|
| September 5, 2025 |
EX-1.1 Exhibit 1.1 SALES AGREEMENT September 5, 2025 CITIZENS JMP SECURITIES, LLC 450 Park Avenue, 5th Floor New York, New York 10022 Ladies and Gentlemen: DBV Technologies S.A., a société anonyme formed under the laws of France, having its registered office at 107 avenue de la République, 92320 Châtillon, France, and registered with the registre du commerce et des sociétés of Nanterre under the n |
|
| July 29, 2025 |
DBV Technologies Reports Second Quarter and Half-Year 2025 Financial Results DBV Technologies Reports Second Quarter and Half-Year 2025 Financial Results DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a clinical-stage biopharmaceutical company, today reported financial results for the Second Quarter of 2025. |
|
| July 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 29, 2025 Date of Report (Date of earliest event reported) DBV Technologies S.A. (Exact name of registrant as specified in its charter) France 001-36697 Not applicable (State or other jurisdiction of incorporation) (Commission Fi |
|
| July 29, 2025 |
BY-LAWS (as updated by the Annual General Meeting on June 11,2025 DBV Technologies Limited Company with share capital of € 13,697,369. |
|
| July 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36697 DBV TECHNOL |
|
| June 25, 2025 |
Exhibit 99.1 DBV Technologies Announces First Subject Screened in COMFORT Toddlers Supplemental Safety Study in Peanut Allergic Toddlers 1 – 3 Years Old • First subject screened at the Respiratory Medicine Research Institute of Michigan with Dr. Jeffrey Leflein acting as Principal Investigator • Additional sites, including Allergy and Asthma Center of Minnesota and Hamilton Allergy and Immunology |
|
| June 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 25, 2025 Date of Report (Date of earliest event reported) DBV Technologies S.A. (Exact name of registrant as specified in its charter) France 001-36697 Not applicable (State or other jurisdiction of incorporation) (Commission Fi |
|
| June 24, 2025 |
Amended and Restated Bylaws (statuts) of the Registrant (English translation) Exhibit 4.1 BY-LAWS (as updated by the Annual General Meeting on June 11, 2025) DBV Technologies Limited Company with share capital of €13,697,369.70 107, avenue de la République - 92320 Châtillon, France Nanterre Trade and Companies Register No. 441 772 522 1 I. - CHARACTERISTIC FEATURES OF THE COMPANY Article 1 - Form The Company was incorporated in the form of a French Limited Company (Société |
|
| June 24, 2025 |
As filed with the Securities and Exchange Commission on June 24, 2025 As filed with the Securities and Exchange Commission on June 24, 2025 Registration No. |
|
| June 24, 2025 |
Calculation of Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) DBV TECHNOLOGIES S. |
|
| June 24, 2025 |
2025 Free Share Plan (English translation) Exhibit 99.2 DBV TECHNOLOGIES PLAN RULES OF THE 2025 FREE SHARE PLAN (INTERNATIONAL VERSION) Purpose and background of the Plan: DBV Technologies (“DBV Technologies” or the “Company”) is granting to its employees a right to receive shares of DBV Technologies for free under this 2025 Free Share Plan (the “Plan”). Through this Plan, employees can become shareholders of DBV Technologies, rewarding th |
|
| June 24, 2025 |
2025 Stock Option Plan (English translation) Exhibit 99.1 DBV TECHNOLOGIES PLAN RULES OF THE 2025 STOCK OPTION PLAN (INTERNATIONAL VERSION) Purpose and background of the Plan: DBV Technologies (“DBV Technologies” or the “Company”) is granting to its employees options to purchase and/or subscribe shares of DBV Technologies under this 2025 Stock Option Plan (the “Plan”). Through this Plan, employees can become shareholders of DBV Technologies, |
|
| June 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 11, 2025 Date of Report (Date of earliest event reported) DBV Technologies S.A. (Exact name of registrant as specified in its charter) France 001-36697 Not applicable (State or other jurisdiction of incorporation) (Commission Fi |
|
| June 11, 2025 |
Amended and Restated By-laws (statuts) of DBV Technologies S.A. (English Translation) Exhibit 3.1 BY-LAWS (as updated by the Annual General Meeting on June 11, 2025) DBV Technologies Limited Company with share capital of €13,697,369.70 107, avenue de la République - 92320 Châtillon, France Nanterre Trade and Companies Register No. 441 772 522 1 I. - CHARACTERISTIC FEATURES OF THE COMPANY Article 1 - Form The Company was incorporated in the form of a French Limited Company (Société |
|
| May 29, 2025 |
Ordinary Shares, which may be represented by American Depositary Shares Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-287393 PROSPECTUS 289,013,065 Ordinary Shares, which may be represented by American Depositary Shares This prospectus relates to the offer and resale from time to time by the selling shareholders named herein of up to 289,013,065 ordinary shares, nominal value €0.10 per share (the “Resale Shares”), which may be represented by |
|
| May 27, 2025 |
CORRESP May 27, 2025 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Tyler Howes Re: DBV Technologies S.A. Registration Statement on Form S-3 Filed May 19, 2025 File No. 333-287393 Acceleration Request Requested Date: May 29, 2025 Requested Time: 4:00 p.m. Eastern Time Dear Tyler Howes: In accordance with Rule 461 un |
|
| May 23, 2025 |
May 23, 2025 Daniel Tass Chief Executive Officer DBV Technologies S.A. 107 avenue de la R publique 92320 Ch tillon France Re: DBV Technologies S.A. Registration Statement on Form S-3 Filed May 19, 2025 File No. 333-287393 Dear Daniel Tass : This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for accel |
|
| May 19, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) DBV Technologies S. |
|
| May 19, 2025 |
As filed with the Securities and Exchange Commission on May 19, 2025 Table of Contents As filed with the Securities and Exchange Commission on May 19, 2025 Registration No. |
|
| May 15, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Def |
|
| May 14, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 2) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to |
|
| May 14, 2025 |
Description of Registered Securities EX-4.5 Exhibit 4.5 DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description of the ordinary shares, the American Depositary Shares and the by-laws of DBV Technologies S.A. (“DBV” or the “Company”) is a summary and does not purport to be complete. This summary is subject to, and qualified in its entirety by reference to, the comple |
|
| May 5, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defi |
|
| April 30, 2025 |
BY-LAWS (updated by decision of the CEO on April 07, 2025) DBV Technologies Limited Company with share capital of € 13,694,887. |
|
| April 30, 2025 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 30, 2025 Date of Report (Date of earliest event reported) DBV Technologies S.A. (Exact name of registrant as specified in its charter) France 001-36697 Not applicable (State or other jurisdiction of incorporation) (Commission F |
|
| April 30, 2025 |
Exhibit 99.1 DBV Technologies Reports First Quarter 2025 Financial Results DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a clinical-stage biopharmaceutical company, today reported financial results for the First Quarter of 2025. The quarterly and three months financial statements were approved by the Board of Directors on April 30, 2025. F |
|
| April 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36697 DBV TECHNO |
|
| April 28, 2025 |
Description of Registered Securities EX-4.5 Exhibit 4.5 DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description of the ordinary shares, the American Depositary Shares and the by-laws of DBV Technologies S.A. (“DBV” or the “Company”) is a summary and does not purport to be complete. This summary is subject to, and qualified in its entirety by reference to, the comple |
|
| April 28, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to |
|
| April 17, 2025 |
X0708 D LIVE 0001613780 DBV Technologies S.A. 107 AVENUE DE LA REPUBLIQUE CHATILLON I0 FRANCE 92320 33(0)155427878 FRANCE None None Corporation true Daniel Tasse c/o DBV Technologies S.A. 107 Avenue de la Republique Chatillon I0 FRANCE 92320 Executive Officer Director Pharis Mohideen c/o DBV Technologies S.A. 107 Avenue de la Republique Chatillon I0 FRANCE 92320 Executive Officer Virginie Boucinha |
|
| April 11, 2025 |
By-laws (status) of the registrant (English translation) Exhibit 3.1 BY-LAWS (updated by decision of the CEO on April 07, 2025) DBV Technologies Limited Company with share capital of € 13,694,887.20 107, avenue de la République - 92320 Châtillon, France Nanterre Trade and Companies Register No. 441 772 522 Exhibit 3.1 I. - CHARACTERISTIC FEATURES OF THE COMPANY Article 1 - Form The Company was incorporated in the form of a French Limited Company (Sociét |
|
| April 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or □ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36697 DBV TECHNOLOGIE |
|
| April 11, 2025 |
Exhibit 19.1 DBV Technologies S.A. Securities Trading Policy January 1, 2024 Warning: This Policy does not, under any circumstances, exempt readers from carefully reading the applicable legal and regulatory provisions. In any event, readers are solely responsible for their actions with respect to the obligations described in the Code. SUMMARY Subject to the exceptions set forth in this Securities |
|
| March 31, 2025 |
NT 10-K SEC FILE NUMBER 001-36697 CUSIP NUMBER 23306J309 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| March 31, 2025 |
Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made and entered into as of March 27, 2025 by and among DBV Technologies S.A., a société anonyme organized under the laws of the French Republic (the “Company”), and the “Investors” who are signatories to this Agreement and to Securities Purchase Agreements, and listed on Annex I-C thereto, dated as |
|
| March 31, 2025 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT DBV TECHNOLOGIES S.A. 107 avenue de la République 92320 Chatillon France The undersigned, [acting in the name and on behalf of the investment funds it represents or advises listed hereafter,] (the “Subscriber”) hereby confirms its agreement with you as follows: 1. This securities purchase agreement (the “Agreement”) is made as of the date set forth below |
|
| March 31, 2025 |
Exhibit 99.1 DBV Technologies Announces Financing of up to $306.9 Million (€284.5 Million) to Advance Viaskin® Peanut Patch Through Biologics License Application Submission and U.S. Commercial Launch, if Approved ● DBV secures $125.5 million (€116.3 million) up front and up to $181.4 million (€168.2 million), subject to the full exercise of warrants ● DBV sufficiently funded through the e |
|
| March 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 27, 2025 Date of Report (Date of earliest event reported) DBV Technologies S.A. (Exact name of registrant as specified in its charter) France 001-36697 Not applicable (State or other jurisdiction of incorporation) (Commission F |
|
| March 24, 2025 |
Exhibit 99.1 DBV Technologies Secures Agreement with FDA on Safety Exposure Data Required for Biologics License Application (BLA) for Viaskin® Peanut Patch in 4 – 7-year-olds, Accelerating the Timeline for a BLA Filing Submission to 1H 2026, and Reports 2024 Unaudited Financial Results1 • COMFORT Children supplemental safety study in children 4 – 7-years-old no longer required • FDA confirms safet |
|
| March 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 24, 2025 Date of Report (Date of earliest event reported) DBV Technologies S.A. (Exact name of registrant as specified in its charter) France 001-36697 Not applicable (State or other jurisdiction of incorporation) (Commission F |
|
| February 14, 2025 |
DBVT / DBV Technologies S.A. - Depositary Receipt (Common Stock) / BRAIDWELL LP Passive Investment SCHEDULE 13G/A 0001140361-23-006949 0001920938 XXXXXXXX LIVE 3 Ordinary shares, nominal value 0. |
|
| January 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 8, 2025 Date of Report (Date of earliest event reported) DBV Technologies S.A. (Exact name of registrant as specified in its charter) France 001-36697 Not applicable (State or other jurisdiction of incorporation) (Commission |
|
| January 8, 2025 |
DBV Technologies Announces Positive Exhibit 99.1 DBV Technologies Announces Positive 3-Year Results from EPITOPE Phase 3 Open-Label Extension Study • EPITOPE OLE data demonstrates continued improvement in treatment benefit of VIASKIN® Peanut patch in toddlers 1 – 3 years through 36 months • 68.2% of subjects completed the oral food challenge (~12-14 peanut kernels) without meeting stopping criteria, compared to 30.7% at month 12 • N |
|
| December 18, 2024 |
EX-10.2 Exhibit 10.2 English Summary Translation of Letter Agreement between Virginie Boucinha and DBV Technologies S.A. Date: December 16, 2024 Parties: DBV Technologies S.A. (the “Company”) and Virginie Boucinha In connection with entry into an agreement (the “Agreement”), which amends that certain Employment Agreement between Ms. Boucinha and the Company, dated as of November 6, 2023, to provid |
|
| December 18, 2024 |
EX-10.1 Exhibit 10.1 December 12, 2024 VIA EMAIL Pharis Mohideen [***] Re: Amendment to Employment Agreement Regarding Enhanced Severance Eligibility Upon A Change in Control Dear Pharis: Thank you for your continued contributions to DBV Technologies Inc. (the “Company”) and DBV Technologies S.A. (the “Parent”). This letter (the “Amendment”) is being executed and delivered to memorialize an amendm |
|
| December 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 16, 2024 Date of Report (Date of earliest event reported) DBV Technologies S.A. (Exact name of registrant as specified in its charter) France 001-36697 Not applicable (State or other jurisdiction of incorporation) (Commissio |
|
| December 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 13, 2024 Date of Report (Date of earliest event reported) DBV Technologies S.A. (Exact name of registrant as specified in its charter) France 001-36697 Not applicable (State or other jurisdiction of incorporation) (Commissio |
|
| December 11, 2024 |
Châtillon, France, December 11 Exhibit 99.1 Press Release Châtillon, France, December 11th, 2024 DBV Confirms Alignment with U.S. FDA on Accelerated Approval Pathway for the Viaskin® Peanut Patch in Toddlers 1 – 3 Years-Old ● DBV and FDA aligned on key study design elements for the COMFORT Toddlers study in 1 – 3 year-olds, including study size and wear time collection methodology and analysis ● COMFORT Toddlers study on- |
|
| December 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 11, 2024 Date of Report (Date of earliest event reported) DBV Technologies S.A. (Exact name of registrant as specified in its charter) France 001-36697 Not applicable (State or other jurisdiction of incorporation) (Commissio |
|
| November 14, 2024 |
DBVT / DBV Technologies S.A. - Depositary Receipt (Common Stock) / BRAIDWELL LP Passive Investment SC 13G/A 1 ef20021615sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* DBV TECHNOLOGIES S.A. (Name of Issuer) Ordinary shares, nominal value €0.10 per share (Title of Class of Securities) 23306J200** (CUSIP Number) September 30, 2024 (Date of Event which Requires Filing of this State |
|
| November 12, 2024 |
Exhibit (a)(i) DBV TECHNOLOGIES S.A. AND CITIBANK, N.A., As Depositary, AND ALL HOLDERS AND BENEFICIAL OWNERS OF AMERICAN DEPOSITARY SHARES OUTSTANDING UNDER THE TERMS OF THE DEPOSIT AGREEMENT, DATED AS OF OCTOBER 24, 2014 Amendment No. 2 to Deposit Agreement Dated as of [●] [●], 2024 TABLE OF CONTENTS Page Article I DEFINITIONS 1 Section 1.01 Definitions 1 Section 1.02 Effective Date 1 Article II |
|
| November 12, 2024 |
DBV Technologies Announces Plan to Implement ADS Ratio Change EX-99.1 Exhibit 99.1 DBV Technologies Announces Plan to Implement ADS Ratio Change DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT—CUSIP: 23306J200), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, today announced plans to change the ratio of its America |
|
| November 12, 2024 |
As filed with the Securities and Exchange Commission on November 12, 2024 Registration No. |
|
| November 12, 2024 |
Exhibit (b)(i) DBV TECHNOLOGIES S.A. May 2, 2022 Citibank, N.A. – ADR Department 388 Greenwich Street New York, NY 10013 Attn: Mr. Brian Teitelbaum Program ADSs (CUSIP No.: 23306J101) Ladies and Gentlemen: Reference is made to the Deposit Agreement, dated as of October 24, 2014, amended and supplemented from time to time (the “Deposit Agreement”), by and among DBV Technologies S.A., a société anon |
|
| November 12, 2024 |
Exhibit (a)(ii) DBV TECHNOLOGIES S.A. AND CITIBANK, N.A., As Depositary, AND ALL HOLDERS AND BENEFICIAL OWNERS OF AMERICAN DEPOSITARY SHARES OUTSTANDING UNDER THE TERMS OF THE DEPOSIT AGREEMENT, DATED AS OF OCTOBER 24, 2014 Amendment No. 1 to the Deposit Agreement Dated as of June 7, 2024 Table of Contents Page Article I DEFINITIONS 1 Section 1.01 Definitions 1 Section 1.02 Effective Date 1 Articl |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 11, 2024 Date of Report (Date of earliest event reported) DBV Technologies S.A. (Exact name of registrant as specified in its charter) France 001-36697 Not applicable (State or other jurisdiction of incorporation) (Commissio |
|
| November 6, 2024 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 6, 2024 Date of Report (Date of earliest event reported) DBV Technologies S.A. (Exact name of registrant as specified in its charter) France 001-36697 Not applicable (State or other jurisdiction of incorporation) (Commission |
|
| November 6, 2024 |
y-laws (statuts) of the registra BY-LAWS (updated by decision of the CEO on September 23, 2024) DBV Technologies Limited Company with share capital of € 9,650,152. |
|
| November 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36697 DBV TE |
|
| November 6, 2024 |
Châtillon, France, November 6, 2024 Exhibit 99.1 Press Release Châtillon, France, November 6, 2024 DBV Technologies Reports Third Quarter 2024 Financial Results DBV closes Q3 2024 with a cash balance of $46.4 million; cash runway into Q1 2025 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J200), a clinical-stage biopharmaceutical company, today reported financial results for the third |
|
| October 22, 2024 |
DBV Announces Positive Regulatory Updates for the Viaskin Exhibit 99.1 DBV Announces Positive Regulatory Updates for the Viaskin® Peanut Patch in the United States and Europe • DBV to pursue an Accelerated Approval pathway for toddlers ages 1 – 3 years-old • BLA submission under Accelerated Approval is subject to completion of a six-month supplemental safety study in toddlers to be initiated in Q2 2025 • VITESSE Phase 3 study evaluating the Viaskin Peanu |
|
| October 22, 2024 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 22, 2024 Date of Report (Date of earliest event reported) DBV Technologies S.A. (Exact name of registrant as specified in its charter) France 001-36697 Not applicable (State or other jurisdiction of incorporation) (Commission |
|
| September 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 23, 2024 Date of Report (Date of earliest event reported) DBV Technologies S.A. (Exact name of registrant as specified in its charter) France 001-36697 Not applicable (State or other jurisdiction of incorporation) (Commissi |
|
| September 23, 2024 |
DBV Technologies Completes Screening for the VITESSE Phase 3 Clinical Trial Exhibit 99.1 DBV Technologies Completes Screening for the VITESSE Phase 3 Clinical Trial • In Q3 2024, DBV exceeded its recruitment goal and successfully closed the screening process for the VITESSE Phase 3 study evaluating the Viaskin® Peanut Patch in peanut allergic children ages 4 – 7 years old • Topline results of VITESSE data are expected by Q4 2025 DBV Technologies (Euronext: DBV – ISIN: FR0 |
|
| July 30, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission fil |
|
| July 30, 2024 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 30, 2024 Date of Report (Date of earliest event reported) DBV Technologies S.A. (Exact name of registrant as specified in its charter) France 001-36697 Not applicable (State or other jurisdiction of incorporation) (Commission Fi |
|
| July 30, 2024 |
Châtillon, France, July 30, 2024 Exhibit 99.1 Châtillon, France, July 30, 2024 DBV Technologies Provides Updates on the Viaskin Peanut Program in Children and Toddlers and Reports Second Quarter and Half-Year 2024 Financial Results • VITESSE enrollment in peanut allergic 4-7-year-olds is on-track and recruitment is expected to be complete by end of Q3 2024 • DBV submitted a labeling proposal, informed by the EPITOPE effic |
|
| July 30, 2024 |
By-laws (statuts) of the registrant (English translation) EX-3.1 Exhibit 3.1 BY-LAWS (updated by decision of the CEO on May 24, 2024) DBV Technologies Limited Company lNith share capital of€ 9,649,307.80 107, avenue de la République - 92320 Châtillon, France Nanterre Trade and Companies Register No. 441 772 522 I. - CHARACTERISTIC FEATURES OF THE COMPANY Article 1 - Form The Company was incorporated in the form of a French Limited Company (Société Anon |
|
| July 2, 2024 |
Amended and Restated Bylaws (statuts) of the Registrant (English translation) Exhibit 4.1 BY-LAWS (updated by decision of the CEO on May 24, 2024) DBV Technologies Limited Company with share capital of € 9,649,307.80 107, avenue de la République - 92320 Châtillon, France Nanterre Trade and Companies Register No. 441 772 522 1 I. - CHARACTERISTIC FEATURES OF THE COMPANY Article 1 - Form The Company was incorporated in the form of a French Limited Company (Société Anonyme) wi |
|
| July 2, 2024 |
Calculation of Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) DBV TECHNOLOGIES S. |
|
| July 2, 2024 |
2024 Free Share Plan (English translation) Exhibit 99.2 DBV TECHNOLOGIES PLAN RULES FOR THE 2024 FREE SHARE PLAN (INTERNATIONAL VERSION) Purpose and background of the Plan: DBV Technologies (“DBV Technologies” or the “Company”) is granting to its employees a right to receive shares of DBV Technologies for free under this 2024 Free Share Plan (the “Plan”). Through this Plan, employees can become shareholders of DBV Technologies, rewarding t |
|
| July 2, 2024 |
As filed with the Securities and Exchange Commission on July 2, 2024 As filed with the Securities and Exchange Commission on July 2, 2024 Registration No. |
|
| July 2, 2024 |
2024 Share Option Plan (English translation) Exhibit 99.1 DBV TECHNOLOGIES PLAN RULES OF THE 2024 STOCK OPTION PLAN (INTERNATIONAL VERSION) Purpose and background of the Plan: DBV Technologies (“DBV Technologies” or the “Company”) is granting to its employees options to purchase and/or subscribe shares of DBV Technologies under this 2024 Stock Option Plan (the “Plan”). Through this Plan, employees can become shareholders of DBV Technologies, |
|
| June 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 18, 2024 Date of Report (Date of earliest event reported) DBV Technologies S.A. (Exact name of registrant as specified in its charter) France 001-36697 Not applicable (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 31, 2024 Date of Report (Date of earliest event reported) DBV Technologies S.A. (Exact name of registrant as specified in its charter) France 001-36697 Not applicable (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 31, 2024 |
Châtillon, France, May 31, 2024 Exhibit 99.1 Châtillon, France, May 31, 2024 DBV Technologies Announces Plan to Implement ADS Ratio Change DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT—CUSIP: 23306J101), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, previously announced plans to ch |
|
| May 17, 2024 |
Exhibit (a)(i) DBV TECHNOLOGIES S.A. AND CITIBANK, N.A., As Depositary, AND ALL HOLDERS AND BENEFICIAL OWNERS OF AMERICAN DEPOSITARY SHARES OUTSTANDING UNDER THE TERMS OF THE DEPOSIT AGREEMENT, DATED AS OF OCTOBER 24, 2014 Amendment No. 1 to Deposit Agreement Dated as of [l], 2024 TABLE OF CONTENTS Article I DEFINITIONS 1 Section 1.01 Definitions 1 Section 1.02 Effective Date 1 Article II AMENDMEN |
|
| May 17, 2024 |
As filed with the Securities and Exchange Commission on May 17, 2024 Registration No. |
|
| May 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 17, 2024 Date of Report (Date of earliest event reported) DBV Technologies S.A. (Exact name of registrant as specified in its charter) France 001-36697 Not applicable (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 17, 2024 |
DBV Technologies Announces Plan to Implement ADS Ratio Change Exhibit 99.1 DBV Technologies Announces Plan to Implement ADS Ratio Change DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT—CUSIP: 23306J101), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, today announced plans to change the ratio of its American Deposi |
|
| May 16, 2024 |
Amended and Restated By-laws (statuts) of DBV Technologies S.A. (English Translation) Exhibit 3.1 BY-LAWS (updated by decision of the CEO on May 16, 2024) DBV Technologies Limited Company with share capital of € 9,643,596.90 107, avenue de la République—92320 Châtillon, France Nanterre Trade and Companies Register No. 441 772 522 1 I. - CHARACTERISTIC FEATURES OF THE COMPANY Article 1 - Form The Company was incorporated in the form of a French Limited Company (Société Anonyme) with |
|
| May 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 16, 2024 Date of Report (Date of earliest event reported) DBV Technologies S.A. (Exact name of registrant as specified in its charter) France 001-36697 Not applicable (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001- |
|
| May 7, 2024 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 7, 2024 Date of Report (Date of earliest event reported) DBV Technologies S.A. (Exact name of registrant as specified in its charter) France 001-36697 Not applicable (State or other jurisdiction of incorporation) (Commission File |
|
| May 7, 2024 |
Exhibit 99.1 Montrouge, France, May 7, 2024 DBV Technologies Reports First Quarter 2024 Financial Results and Business Update ● VITESSE enrollment on track to screen last patient by Q3 2024 ● Appointment of Robert Pietrusko, PharmD to Chief Regulatory Officer ● Q1 2024 closes with a cash balance of $101.5 million DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a |
|
| May 7, 2024 |
By-laws (status) of the registrant (English translation) Exhibit 3.1 BY-LAWS (updated by decision of the CEO on March 23, 2024) DBV Technologies Limited Company with share capital of € 9,643,436.90 177-181 avenue Pierre Brossolette - 92120 Montrouge, France Nanterre Trade and Companies Register No. 441 772 522 1 I. - CHARACTERISTIC FEATURES OF THE COMPANY Article 1 - Form The Company was incorporated in the form of a French Limited Company (Société Anon |
|
| April 26, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi |
|
| April 26, 2024 |
DBVTechnologies S.A. 2023 Annual Report to Securityholders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) È ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ‘ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition peri |
|
| April 8, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defi |
|
| March 8, 2024 |
DBV Technologies announces filing of 2023 Annual Report on Form Exhibit 99.1 DBV Technologies announces filing of 2023 Annual Report on Form 10-K and Universal Registration Document DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need (the “Company”), today announced the fi |
|
| March 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 8, 2024 Date of Report (Date of earliest event reported) DBV Technologies S.A. (Exact name of registrant as specified in its charter) France 001-36697 Not applicable (State or other jurisdiction of incorporation) (Commission Fi |
|
| March 7, 2024 |
Exhibit 10.37 BETWEEN THE UNDERSIGNED: DBV Technologies, a French public limited company (société anonyme) with share capital of 9,625,355.30 euros, registered in the Nanterre Trade Register under number 441 772 522, with its head office at 171-181, avenue Pierre Brossolette 92120 Montrouge, represented by Caroline Danière, in her capacity as Group Human Resources Director, duly authorized to act |
|
| March 7, 2024 |
List of subsidiaries of the registrant Exhibit 21.1 Subsidiaries Name of Subsidiary State or Other Jurisdiction of Incorporation DBV Technologies Inc. Delaware, United State of America DBV Technologies Australia PTY Ltd. New South Wales, Australia DBV Pharma S.A.S. France |
|
| March 7, 2024 |
Exhibit 10.36 English Summary Translation of Separation Agreement and Release between Sébastien Robitaille and DBV Technologies S.A. Date: October 30, 2023 Parties: DBV Technologies S.A. (the “Company”) and Sébastien Robitaille In connection with Mr. Robitaille’s departure from his position as Chief Financial Officer of the Company, among other things: • Mr. Robitaille will continue to serve as an |
|
| March 7, 2024 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 7, 2024 Date of Report (Date of earliest event reported) DBV Technologies S.A. (Exact name of registrant as specified in its charter) France 001-36697 Not applicable (State or other jurisdiction of incorporation) (Commission Fi |
|
| March 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36697 DBV |
|
| March 7, 2024 |
Exhibit 10.2 COMMERCIAL LEASE BETWEEN: SCI DANTON MALAKOFF, a French non-trading real estate company with share capital of 1,000 euros, registered in the Paris Trade and Companies Register under number 838 690 071, whose registered office is located at 30 avenue Kleber 75116 PARIS, Represented by Céline Leonardi, Marketing Director, duly empowered for the purposes hereof, Hereinafter referred to a |
|
| March 7, 2024 |
Lease Agreement between DBV Technologies Inc. and SIG 106 LLC, dated March 28, 2022 Exhibit 10.3 LEASE AGREEMENT This LEASE AGREEMENT (this “Lease”) is dated MARCH 28, 2022, and is between SIG 106 LLC, a New Jersey limited liability company (“Landlord”), and DBV TECHNOLOGIES, INC., a Delaware corporation (“Tenant”). Landlord is the owner of certain real property located at 106 Allen Road, Basking Ridge, Bernards Township, New Jersey (“Real Property”) and that certain multi-level |
|
| March 7, 2024 |
By-laws (status) of the registrant (English translation) Exhibit 3.1 BY-LAWS (updated by decision of the CEO on November 24, 2023) DBV Technologies Limited Company with share capital of € 9,643,177 177-181 avenue Pierre Brossolette - 92120 Montrouge, France Nanterre Trade and Companies Register No. 441 772 522 1 I. - CHARACTERISTIC FEATURES OF THE COMPANY Article 1 - Form The Company was incorporated in the form of a French Limited Company (Société Anon |
|
| March 7, 2024 |
Montrouge, France, March 7, 2024 Exhibit 99.1 Press Release Montrouge, France, March 7, 2024 DBV Technologies Reports Full Year 2023 Financial Results and Business Update • Advanced Viaskin™ Peanut clinical development programs in peanut-allergic toddlers (1 through 3 years old) and children (4 through 7 years old) • Strengthened executive leadership team in preparation for BLA submission • Reported cash and cash equivalents of $ |
|
| March 7, 2024 |
Incentive Compensation Recoupment Policy, approved Exhibit 97.1 DBV TECHNOLOGIES S.A. INCENTIVE COMPENSATION RECOUPMENT POLICY 1. INTRODUCTION The Board of Directors (the “Board”) of DBV Technologies S.A., a société anonyme organized under the laws of France (the “Company”), upon recommendation of the Compensation Committee of the Board (the “Compensation Committee”), has determined that it is in the best interests of the Company and its sharehold |
|
| March 7, 2024 |
Exhibit 10.7 26 October 2023 Société des Produits Nestlé S.A. (formerly named NESTEC S.A.) 55, Avenue Nestlé CH-1800 Vevey Switzerland Attn: Claudio Kuoni General Counsel of Nestlé Health Science Re: Termination of the Development Collaboration and License Agreement Dear Mr. Kuoni: Reference is made herein to that certain Development Collaboration and License Agreement, dated 27 May 2016, as amend |
|
| February 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* DBV Technologies S.A. (Name of Issuer) Ordinary Shares, €0.10 nominal value per share (Title of Class of Securities) 23306J101 (American Depositary Shares, each representing one-half of one Ordinary Share) (CUSIP Number) December 31, 2023 (Date of Even |
|
| February 14, 2024 |
SC 13G/A 1 ef20021615sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* DBV TECHNOLOGIES S.A. (Name of Issuer) Ordinary shares, nominal value €0.10 per share (Title of Class of Securities) 23306J101** (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statem |
|
| December 22, 2023 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 20, 2023 Date of Report (Date of earliest event reported) DBV Technologies S.A. (Exact name of registrant as specified in its charter) France 001-36697 Not applicable (State or other jurisdiction of incorporation) (Commissio |
|
| November 20, 2023 |
2022 Stock Option Plan (English translation) Exhibit 99.3 DBV TECHNOLOGIES PLAN RULES OF THE 2022 STOCK OPTION PLAN (INTERNATIONAL VERSION) Purpose and background of the Plan: DBV Technologies (“DBV Technologies” or the “Company”) is granting to its employees options to purchase and/or subscribe shares of DBV Technologies under this 2022 Stock Option Plan (the “Plan”). Through this Plan, employees can become shareholders of DBV Technologies, |
|
| November 20, 2023 |
2023 Free Share Plan (English translation) Exhibit 99.2 DBV TECHNOLOGIES PLAN RULES FOR THE 2023 FREE SHARE PLAN (INTERNATIONAL VERSION) Purpose and background of the Plan: DBV Technologies (“DBV Technologies” or the “Company”) is granting to its employees a right to receive shares of DBV Technologies for free under this 2023 Free Share Plan (the “Plan”). Through this Plan, employees can become shareholders of DBV Technologies, rewarding t |
|
| November 20, 2023 |
Calculation of Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) DBV TECHNOLOGIES S. |
|
| November 20, 2023 |
Bylaws (statuts) of the Registrant (English translation) Exhibit 4.1 BY-LAWS (updated by decision of the CEO on October 25, 2023) DBV Technologies Limited Company with share capital of € 9,628,855.30 177-181 avenue Pierre Brossolette - 92120 Montrouge, France Nanterre Trade and Companies Register No. 441 772 522 1 I. - CHARACTERISTIC FEATURES OF THE COMPANY Article 1 - Form The Company was incorporated in the form of a French Limited Company (Société An |
|
| November 20, 2023 |
2023 Share Option Plan (English translation) Exhibit 99.1 DBV TECHNOLOGIES PLAN RULES OF THE 2023 STOCK OPTION PLAN (INTERNATIONAL VERSION) Purpose and background of the Plan: DBV Technologies (“DBV Technologies” or the “Company”) is granting to its employees options to purchase and/or subscribe shares of DBV Technologies under this 2023 Stock Option Plan (the “Plan”). Through this Plan, employees can become shareholders of DBV Technologies, |
|
| November 20, 2023 |
As filed with the Securities and Exchange Commission on November 20, 2023 As filed with the Securities and Exchange Commission on November 20, 2023 Registration No. |
|
| November 9, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 9, 2023 Date of Report (Date of earliest event reported) DBV Technologies S.A. (Exact name of registrant as specified in its charter) France 001-36697 Not applicable (State or other jurisdiction of incorporation) (Commission |
|
| November 9, 2023 |
Montrouge, France, November 9, 2023 Exhibit 99.1 Press Release Montrouge, France, November 9, 2023 DBV Technologies Announces 2-Year Results from Ongoing Phase 3 Open-Label Extension to the EPITOPE Trial (EPOPEX) of Viaskin™ Peanut in Toddlers ● Viaskin Peanut showed improvement between months 12 and 24 of treatment across all efficacy parameters. Notably, 81.3% of subjects who completed the oral food challenge reached an eliciting |
|
| November 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 16, 2023 Date of Report (Date of earliest event reported) DBV Technologies S.A. (Exact name of registrant as specified in its charter) France 001-36697 Not applicable (State or other jurisdiction of incorporation) (Commissi |
|
| November 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 16, 2023 Date of Report (Date of earliest event reported) DBV Technologies S.A. (Exact name of registrant as specified in its charter) France 001-36697 Not applicable (State or other jurisdiction of incorporation) (Commissi |
|
| October 31, 2023 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 30, 2023 Date of Report (Date of earliest event reported) DBV Technologies S.A. (Exact name of registrant as specified in its charter) France 001-36697 Not applicable (State or other jurisdiction of incorporation) (Commission |
|
| October 31, 2023 |
Exhibit 99.1 DBV Technologies Receives Requested Feedback from FDA on Protocol Design Elements for COMFORT Safety Studies and Reports Third Quarter 2023 Financial Results ● DBV has received written feedback from the U.S. Food and Drug Administration (FDA) clarifying design elements for both the COMFORT Toddlers and COMFORT Children supplemental safety studies. ● Both supplemental safety stud |
|
| October 31, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commissio |
|
| October 16, 2023 |
Montrouge, France, October 16, 2023 Exhibit 99.1 Montrouge, France, October 16, 2023 DBV Technologies Announces Appointment of Virginie Boucinha as Chief Financial Officer DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced the appointment of Virginie Boucinha as its Chief Financial Officer, effective November 6, 2023. An experienced financial |
|
| October 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 16, 2023 Date of Report (Date of earliest event reported) DBV Technologies S.A. (Exact name of registrant as specified in its charter) France 001-36697 Not applicable (State or other jurisdiction of incorporation) (Commission |
|
| July 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 31, 2023 Date of Report (Date of earliest event reported) DBV Technologies S.A. (Exact name of registrant as specified in its charter) France 001-36697 Not applicable (State or other jurisdiction of incorporation) (Commission Fi |
|
| July 31, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001 |
|
| July 31, 2023 |
EX-99.1 Exhibit 99.1 Press Release Montrouge, France, July 31, 2023 DBV Technologies Receives Feedback from FDA on Design Elements for Viaskin Peanut Safety Studies and Reports Second Quarter and Half-Year 2023 Financial Results ● Received feedback from U.S. Food and Drug Administration (FDA) on DBV’s two supplemental safety studies in toddlers (ages 1 – 3 years) and children (ages 4 – 7 years). ● |
|
| May 11, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 10, 2023 Date of Report (Date of earliest event reported) DBV Technologies S.A. (Exact name of registrant as specified in its charter) France 001-36697 Not applicable (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 11, 2023 |
EX-99.1 Exhibit 99.1 DBV Technologies Announces New England Journal of Medicine Publication of Phase 3 EPITOPE Trial Data Evaluating Viaskin™ Peanut in Toddlers • The New England Journal of Medicine (NEJM) published results that demonstrated epicutaneous immunotherapy (EPITTM) with Viaskin Peanut was statistically superior to placebo in desensitizing children to peanut by increasing the peanut dos |
|
| May 4, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 00 |
|
| May 4, 2023 |
By-laws (statuts) of the registrant (English translation) EX-3.1 Exhibit 3.1 BY-LAWS (updated further to the Shareholders General Meeting on April 12, 2023) DBV Technologies Limited Company with share capital of €9,414,731.90 177-181 avenue Pierre Brossolette - 92120 Montrouge, France Nanterre Trade and Companies Register No. 441 772 522 1 I. - CHARACTERISTIC FEATURES OF THE COMPANY Article 1 - Form The Company was incorporated in the form of a French Li |
|
| May 4, 2023 |
EX-99.1 Exhibit 99.1 DBV Technologies Reports First Quarter 2023 Financial Results • DBV closes Q1 2023 with cash and cash equivalents of $192.3 million. DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today reported financial results for the first quarter of 2023. The quarterly financial statements were approved by the |
|
| May 4, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 4, 2023 Date of Report (Date of earliest event reported) DBV Technologies S.A. (Exact name of registrant as specified in its charter) France 001-36697 Not applicable (State or other jurisdiction of incorporation) (Commission File |
|
| April 20, 2023 |
DBV Technologies Outlines Regulatory Path for Viaskin Peanut in Children 1 – 3 Years After Receiving EX-99.1 Exhibit 99.1 DBV Technologies Outlines Regulatory Path for Viaskin Peanut in Children 1 – 3 Years After Receiving Pre-BLA Responses from FDA • The FDA confirmed that the Company’s Phase 3 EPITOPE study met the pre-specified criteria for success for the primary endpoint and did not request an additional efficacy study. • Additional safety data will be required to augment the safety data col |
|
| April 20, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 19, 2023 Date of Report (Date of earliest event reported) DBV Technologies S.A. (Exact name of registrant as specified in its charter) France 001-36697 Not applicable (State or other jurisdiction of incorporation) (Commission F |
|
| April 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 12, 2023 Date of Report (Date of earliest event reported) DBV Technologies S.A. (Exact name of registrant as specified in its charter) France 001-36697 Not applicable (State or other jurisdiction of incorporation) (Commission F |
|
| April 13, 2023 |
United States securities and exchange commission logo April 13, 2023 Michele Robertson Chief Legal Officer, Vice President DBV Technologies S. |
|
| April 13, 2023 |
DBV TECHNOLOGIES S.A. 177-181 Avenue Pierre Brossolette 92120 Montrouge France CORRESP DBV TECHNOLOGIES S.A. 177-181 Avenue Pierre Brossolette 92120 Montrouge France April 13, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Daniel Crawford RE: DBV Technologies S.A. Registration Statement on Form S-3 File No. 333-271166 Acceleration Request Requested Date: Monday, April 17, 2023 Re |
|
| April 6, 2023 |
As filed with the Securities and Exchange Commission on April 6, 2023 S-3 Table of Contents As filed with the Securities and Exchange Commission on April 6, 2023 Registration No. |
|
| April 6, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) DBV Technologies S. |
|
| March 24, 2023 |
DBVTechnologies S.A. 2022 Annual Report to Securityholders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) È ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ‘ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition peri |
|
| March 24, 2023 |
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| March 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 10, 2023 Date of Report (Date of earliest event reported) DBV Technologies S.A. (Exact name of registrant as specified in its charter) France 001-36697 Not applicable (State or other jurisdiction of incorporation) (Commission F |
|
| March 8, 2023 |
PRE 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| March 7, 2023 |
DBV Technologies Announces First Patient EX-99.1 Exhibit 99.1 DBV Technologies Announces First Patient Screened in VITESSE Phase 3 Clinical Trial in Peanut-Allergic Children 4 – 7 Years Old • First patient screened at Midwest Allergy Sinus Asthma in Normal, Illinois in the VITESSE Clinical Trial • VITESSE is DBV’s Phase 3 clinical study evaluating the modified Viaskin Peanut patch in peanut-allergic children ages 4 –7 years old DBV Techn |
|
| March 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 7, 2023 Date of Report (Date of earliest event reported) DBV Technologies S.A. (Exact name of registrant as specified in its charter) France 001-36697 Not applicable (State or other jurisdiction of incorporation) (Commission Fi |
|
| March 3, 2023 |
Montrouge, France, March 2, 2023 Exhibit 99.2 Montrouge, France, March 2, 2023 DBV Technologies announces filing of 2022 Annual Report on Form 10-K and 2022 Universal Registration Document DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company (the “Company”), today announced the filing of its Annual Report on Form 10-K for the year ended December 31, 2022, wi |
|
| March 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 2, 2023 Date of Report (Date of earliest event reported) DBV Technologies S.A. (Exact name of registrant as specified in its charter) France 001-36697 Not applicable (State or other jurisdiction of incorporation) (Commission Fi |
|
| March 3, 2023 |
Montrouge, France, March 2, 2023 EX-99.1 Exhibit 99.1 Montrouge, France, March 2, 2023 DBV Technologies Reports Full Year 2022 Financial Results and Business Update • DBV completed EVOLVE, a 12-week caregiver and patient user experience study of the modified Viaskin Peanut patch in peanut-allergic children ages 4 – 11 years old • DBV had $209.2 million in Cash and Cash Equivalents at December 31, 2022. DBV Technologies (Euronext: |
|
| March 2, 2023 |
2022 Share Option Plan (English translation) EX-10.24 Exhibit 10.24 DBV TECHNOLOGIES PLAN RULES OF THE 2022 STOCK OPTION PLAN (INTERNATIONAL VERSION) Purpose and background of the Plan: DBV Technologies (“DBV Technologies” or the “Company”) is granting to its employees options to purchase and/or subscribe shares of DBV Technologies under this 2022 Stock Option Plan (the “Plan”). Through this Plan, employees can become shareholders of DBV Tec |
|
| March 2, 2023 |
By-laws (statuts) of the registrant (English translation) EX-3.1 Exhibit 3.1 BY-LAWS (updated by decision of the CEO on November 28, 2022) DBV Technologies Limited Company with share capital of €9,413,714.50 177-181 avenue Pierre Brossolette - 92120 Montrouge, France Nanterre Trade and Companies Register No. 441 772 522 1 I. - CHARACTERISTIC FEATURES OF THE COMPANY Article 1 - Form The Company was incorporated in the form of a French Limited Company (Soc |
|
| March 2, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-366 |
|
| March 2, 2023 |
2022 Free Share Plan (English translation) EX-10.25 Exhibit 10.25 DBV TECHNOLOGIES PLAN RULES FOR THE 2022 FREE SHARE PLAN (INTERNATIONAL VERSION) Purpose and background of the Plan: DBV Technologies (“DBV Technologies” or the “Company”) is granting to its employees a right to receive shares of DBV Technologies for free under this 2022 Free Share Plan (the “Plan”). Through this Plan, employees can become shareholders of DBV Technologies, r |
|
| February 14, 2023 |
SC 13G/A 1 tm236635d6sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* DBV Technologies S.A. (Name of Issuer) Ordinary Shares, €0.10 nominal value per share (Title of Class of Securities) 23306J101 (American Depositary Shares, each representing one-half of one Ordinary Share) (CUSI |
|
| February 14, 2023 |
DBVT / DBV Technologies S.A. / BRAIDWELL LP - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* DBV TECHNOLOGIES S.A. (Name of Issuer) Ordinary shares, nominal value €0.10 per share (Title of Class of Securities) 23306J101** (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designat |
|
| December 23, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 23, 2022 Date of Report (Date of earliest event reported) DBV Technologies S.A. (Exact name of registrant as specified in its charter) France 001-36697 Not applicable (State or other jurisdiction of incorporation) (Commissio |
|
| December 23, 2022 |
DBV Technologies Announces FDA Has Lifted Partial Clinical Hold on VITESSE Phase 3 Pivotal Trial Exhibit 99.1 DBV Technologies Announces FDA Has Lifted Partial Clinical Hold on VITESSE Phase 3 Pivotal Trial ? DBV expects to initiate patient screening in Q1 2023 with the last patient screened by 1H 2024 and topline results anticipated in 1H 2025 ? Company reiterates that cash on-hand is sufficient to fund operations through VITESSE topline data DBV Technologies (Euronext: DBV ? ISIN: FR0010417 |
|
| November 3, 2022 |
By-laws (status) of the registrant (English translation) Exhibit 3.1 BY-LAWS (updated by decision of the CEO on October 14, 2022) DBV Technologies Limited Company with share capital of ?9,402,544.10 177-181 avenue Pierre Brossolette - 92120 Montrouge, France Nanterre Trade and Companies Register No. 441 772 522 1 I. - CHARACTERISTIC FEATURES OF THE COMPANY Article 1 - Form The Company was incorporated in the form of a French Limited Company (Soci?t? Ano |
|
| November 3, 2022 |
Nine months ended September 30, EX-99.1 2 d411212dex991.htm EX-99.1 Exhibit 99.1 DBV Technologies Reports Third Quarter Financial Results and Business Update • DBV closes Q3 with a cash balance of $213M • DBV continues to practice budget discipline measures; cash used in operating activities decreased more than 35% between the nine months ended September 30, 2021 and 2022 • DBV continues to engage with the U.S. Food and Drug Adm |
|
| November 3, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe |
|
| November 3, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 3, 2022 Date of Report (Date of earliest event reported) DBV Technologies S.A. (Exact name of registrant as specified in its charter) France 001-36697 Not applicable (State or other jurisdiction of incorporation) (Commission |
|
| October 4, 2022 |
Montrouge, France, October 3, 2022 Exhibit 99.1 Montrouge, France, October 3, 2022 DBV Technologies Announces Appointment of New Chair of its Audit Committee and Appointment of Daniele Guyot-Caparros to Board of Directors DBV Technologies (Euronext: DBV ? ISIN: FR0010417345 ? Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that Mr. Timothy E. Morris, Independent Director and Member of the Aud |
|
| October 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 3, 2022 Date of Report (Date of earliest event reported) DBV Technologies S.A. (Exact name of registrant as specified in its charter) France 001-36697 Not applicable (State or other jurisdiction of incorporation) (Commission |
|
| September 22, 2022 |
DBV Technologies Provides Clinical Update on VITESSE Phase 3 Trial Exhibit 99.1 DBV Technologies Provides Clinical Update on VITESSE Phase 3 Trial DBV Technologies (Euronext: DBV ? ISIN: FR0010417345 ? Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that it received feedback from the U.S. Food and Drug Administration (FDA) in the form of a partial clinical hold on its VITESSE (Viaskin Peanut Immunotherapy Trial to Evaluate |
|
| September 22, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 21, 2022 Date of Report (Date of earliest event reported) DBV Technologies S.A. (Exact name of registrant as specified in its charter) France 001-36697 Not applicable (State or other jurisdiction of incorporation) (Commissi |
|
| September 8, 2022 |
Exhibit 99.1 DBV Technologies Announces Initiation of Phase 3 Study (VITESSE) Using the Modified Viaskin Peanut Patch in Peanut-Allergic Children Ages 4 to 7 Years ? DBV has finalized the VITESSE protocol after productive exchanges with the U.S. Food and Drug Administration (FDA) concerning key study design elements ? DBV expects to screen the first patient in Q4 2022 and anticipates topline resul |
|
| September 8, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 7, 2022 Date of Report (Date of earliest event reported) DBV Technologies S.A. (Exact name of registrant as specified in its charter) France 001-36697 Not applicable (State or other jurisdiction of incorporation) (Commissio |
|
| August 11, 2022 |
Ordinary Shares, which may be represented by American Depositary Shares Table of Contents Filed Pursuant to Rule 424(b)(3) Registration Statement No. 333-266448 PROSPECTUS 11,593,170 Ordinary Shares, which may be represented by American Depositary Shares This prospectus relates to the proposed resale from time to time of up to 11,593,170 ordinary shares, nominal value €0.10 per share (the “Resale Shares”), which may be represented by American Depositary Shares, or ADS |
|
| August 11, 2022 |
Ordinary Shares, which may be represented by American Depositary Shares Table of Contents Filed Pursuant to Rule 424(b)(3) Registration Statement No. 333-266449 PROSPECTUS 59,269,629 Ordinary Shares, which may be represented by American Depositary Shares This prospectus relates to the proposed resale from time to time of up to 59,269,629 ordinary shares, nominal value ?0.10 per share (the ?Resale Shares?), which may be represented by American Depositary Shares, or ADS |
|
| August 9, 2022 |
DBV TECHNOLOGIES S.A. 177-181 Avenue Pierre Brossolette 92120 Montrouge France DBV TECHNOLOGIES S.A. 177-181 Avenue Pierre Brossolette 92120 Montrouge France August 9, 2022 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Dillon Hagius RE: DBV Technologies S.A. Registration Statement on Form S-3 File No. 333-266449 Acceleration Request Requested Date: Thursday, August 11, 2022 Requested |
|
| August 9, 2022 |
DBV TECHNOLOGIES S.A. 177-181 Avenue Pierre Brossolette 92120 Montrouge France DBV TECHNOLOGIES S.A. 177-181 Avenue Pierre Brossolette 92120 Montrouge France August 9, 2022 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Dillon Hagius RE: DBV Technologies S.A. Registration Statement on Form S-3 File No. 333-266448 Acceleration Request Requested Date: Thursday, August 11, 2022 Requested |
|
| August 5, 2022 |
United States securities and exchange commission logo August 5, 2022 Daniel Tass Chief Executive Officer DBV Technologies S. |
|
| August 5, 2022 |
United States securities and exchange commission logo August 5, 2022 Daniel Tass Chief Executive Officer DBV Technologies S. |
|
| August 1, 2022 |
Exhibit 99.1 Press Release Montrouge, France, August 1, 2022 DBV Technologies Reports Second Quarter 2022 Financial Results ? DBV closes Q2 with a cash balance of $248M following recent ATM and PIPE offerings ? DBV continues to practice budget discipline measures; cash used in operating activities decreased more than 40% between the first half of 2021 and 2022 ? The U.S. District Court, District o |
|
| August 1, 2022 |
As filed with the Securities and Exchange Commission on August 1, 2022 Table of Contents As filed with the Securities and Exchange Commission on August 1, 2022 Registration No. |
|
| August 1, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) DBV Technologies S. |
|
| August 1, 2022 |
Amended and Restated By-laws (statuts) of the registrant (English translation) Exhibit 3.1 B Y-LAWS (updated by decision of the CEO on July 12, 2022) DBV Technologies Limited Company with share capital of ?9,402,267.90 177-181 avenue Pierre Brossolette - 92120 Montrouge, France Nanterre Trade and Companies Register No. 441 772 522 1 I.?CHARACTERISTIC FEATURES OF THE COMPANY Article 1 - Form The Company was incorporated in the form of a French Limited Company (Soci?t? Anonyme |
|
| August 1, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 1, 2022 Date of Report (Date of earliest event reported) DBV Technologies S.A. (Exact name of registrant as specified in its charter) France 001-36697 Not applicable (State or other jurisdiction of incorporation) (Commission F |
|
| August 1, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) DBV Technologies S. |
|
| August 1, 2022 |
As filed with the Securities and Exchange Commission on August 1, 2022 Table of Contents As filed with the Securities and Exchange Commission on August 1, 2022 Registration No. |
|
| August 1, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001 |
|
| July 18, 2022 |
As filed with the Securities and Exchange Commission on July 18, 2022 Registration No. |
|
| July 18, 2022 |
Exhibit (e) Rule 466 Certification The depositary, Citibank, N.A., represents and certifies the following: (a) That it previously had filed a registration statement on Form F-6 (Registration No. 333-265201), which the U.S. Securities and Exchange Commission declared effective, with terms of deposit identical to the terms of deposit of this Form F-6 Registration Statement and (b) That its ability t |
|
| July 18, 2022 |
Exhibit (d) July 18, 2022 Citibank, N.A. ? ADR Department 388 Greenwich Street New York, New York 10013 Ladies and Gentlemen: We refer to the Registration Statement on Form F-6 (the ?Registration Statement?) to be filed with the Securities and Exchange Commission (the ?SEC?) by the legal entity created by the Deposit Agreement (as hereinafter defined) for the purpose of registering under the Unite |
|
| June 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* DBV Technologies S.A. (Name of Issuer) Ordinary Shares, €0.10 nominal value per share (Title of Class of Securities) 23306J101 (American Depositary Shares, each representing one-half of one Ordinary Share) (CUSIP Number) June 13, 2022 (Date of Event Which |
|
| June 16, 2022 |
DBVT / DBV Technologies S.A. / Bpifrance Participations SA - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 5)* DBV Technologies S.A. (Name of Issuer) Ordinary Shares, nominal value €0.10 per share (Title of Class of Securities) 23306J101 (American Depositary Shares, each representing one-half of one Ordinary Share) (CUSIP Number) Sophie Paquin Bpifrance Participa |
|
| June 13, 2022 |
DBVT / DBV Technologies S.A. / BAKER BROS. ADVISORS LP - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. |
|
| June 13, 2022 |
DBV Technologies Announces Private Placement Financing of $194 Million Exhibit 99.1 Montrouge, France, June 9, 2022 DBV Technologies Announces Private Placement Financing of $194 Million DBV Technologies (Euronext: DBV ? ISIN: FR0010417345 ? Nasdaq Global Select Market: DBVT), a clinical-stage biopharmaceutical company, today announced an aggregate $194 million private investment in public equity (PIPE) financing (corresponding to ?181 million on the basis of an exch |
|
| June 13, 2022 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT DBV TECHNOLOGIES S.A. 177-181 avenue Pierre Brossolette 92120 Montrouge France The undersigned (the ?Subscribers?) hereby confirm their agreement with you as follows: 1. This Securities Purchase Agreement (the ?Agreement?) is made as of the date set forth below between DBV Technologies S.A., a societ? anonyme organized under the laws of the French Republi |
|
| June 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 8, 2022 Date of Report (Date of earliest event reported) DBV Technologies S.A. (Exact name of registrant as specified in its charter) France 001-36697 Not applicable (State or other jurisdiction of incorporation) (Commission Fil |
|
| June 13, 2022 |
Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (this ?Agreement?) is made and entered into as of June 8, 2022 by and among DBV Technologies S.A., a soci?t? anonyme organized under the laws of the French Republic (the ?Company?), and the ?Investors? named in the Securities Purchase Agreement, dated as of the date hereof, by and among the Company and the Investors iden |
|
| June 7, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 7, 2022 Date of Report (Date of earliest event reported) DBV Technologies S.A. (Exact name of registrant as specified in its charter) France 001-36697 Not applicable (State or other jurisdiction of incorporation) (Commission Fil |
|
| June 7, 2022 |
Montrouge, France, June 7, 2022 Exhibit 99.1 Montrouge, France, June 7, 2022 DBV Technologies Announces Positive Topline Results from Phase 3 EPITOPE Trial of Viaskin Peanut in Peanut-Allergic Toddlers ? 67.0% of subjects treated with Viaskin Peanut 250 ?g met response criteria at 12 months, compared with 33.5% of subjects in the placebo arm ? Pivotal trial met primary endpoint: lower bound of the 95% confidence interval (CI) of |
|
| May 25, 2022 |
Exhibit (a) DEPOSIT AGREEMENT by and among DBV TECHNOLOGIES S.A. AND CITIBANK, N.A., as Depositary, AND THE HOLDERS AND BENEFICIAL OWNERS OF AMERICAN DEPOSITARY SHARES ISSUED HEREUNDER Dated as of October 24, 2014 TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 1 Section 1.1 ?ADS Record Date? 1 Section 1.2 ?Affiliate? 2 Section 1.3 ?American Depositary Receipt(s)?, ?ADR(s)? and ?Receipt(s)? 2 Section |
|
| May 25, 2022 |
Exhibit (d) May 25, 2022 Citibank, N.A. ? ADR Department 388 Greenwich Street New York, New York 10013 Ladies and Gentlemen: We refer to the Registration Statement on Form F-6 (the ?Registration Statement?) to be filed with the Securities and Exchange Commission (the ?SEC?) by the legal entity created by the Deposit Agreement (as hereinafter defined) for the purpose of registering under the United |
|
| May 25, 2022 |
Exhibit (e) Rule 466 Certification The depositary, Citibank, N.A., represents and certifies the following: (a) That it previously had filed a registration statement on Form F-6 (Registration No. 333-199231), which the U.S. Securities and Exchange Commission declared effective, with terms of deposit identical to the terms of deposit of this Form F-6 Registration Statement and (b) That its ability t |
|
| May 25, 2022 |
As filed with the Securities and Exchange Commission on May 25, 2022 Registration No. |
|
| May 16, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 12, 2022 Date of Report (Date of earliest event reported) DBV Technologies S.A. (Exact name of registrant as specified in its charter) France 001-36697 Not applicable (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 2, 2022 |
Up to $100,000,000 of Ordinary Shares American Depositary Shares 424B5 1 d231045d424b5.htm 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration Statement File No. 333-257569 PROSPECTUS SUPPLEMENT (TO PROSPECTUS DATED JULY 16, 2021) Up to $100,000,000 of Ordinary Shares American Depositary Shares We have entered into a sales agreement, or the Sales Agreement, with Jefferies LLC, or Jefferies, relating to the sale of American Depositary Shares, o |
|
| May 2, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 2, 2022 Date of Report (Date of earliest event reported) DBV Technologies S.A. (Exact name of registrant as specified in its charter) France 001-36697 Not applicable (State or other jurisdiction of incorporation) (Commission File |
|
| May 2, 2022 |
By-laws (statuts) of the registrant (English translation) Exhibit 3.1 BY-LAWS (updated by decision of the CEO on March 23, 2022) DBV Technologies Limited Company with share capital of ?5,509,653.70 177-181 avenue Pierre Brossolette - 92120 Montrouge, France Nanterre Trade and Companies Register No. 441 772 522 1 I. - CHARACTERISTIC FEATURES OF THE COMPANY Article 1 - Form The Company was incorporated in the form of a French Limited Company (Soci?t? Anony |
|
| May 2, 2022 |
Exhibit 99.1 Press Release Montrouge, France, May 2, 2022 DBV Technologies Reports Recent Business Developments and First Quarter 2022 Financial Results ? The U.S. Food and Drug Administration (FDA) has granted DBV Technologies a Type C meeting to align on the new Viaskin Peanut Phase 3 study protocol ? The study protocol was recently submitted to the FDA as part of the Type C briefing materials D |
|
| May 2, 2022 |
DBV Technologies Establishes an Exhibit 99.1 DBV Technologies Establishes an At-The-Market (ATM) Program on Nasdaq DBV Technologies (Euronext: DBV ? ISIN: FR0010417345 ? Nasdaq Global Select Market: DBVT) (the ?Company?), a clinical-stage biotechnological company, today announced that it has filed a prospectus supplement with the U.S. Securities and Exchange Commission (?SEC?) relating to an At-The-Market offering (the ?ATM Prog |
|
| May 2, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 2, 2022 Date of Report (Date of earliest event reported) DBV Technologies S.A. (Exact name of registrant as specified in its charter) France 001-36697 Not applicable (State or other jurisdiction of incorporation) (Commission File |
|
| May 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36697 DBV TECHNO |
|
| May 2, 2022 |
Sales Agreement, dated as of May 2, 2022, by and between DBV Technologies S.A. and Jefferies LLC Exhibit 1.1 SALES AGREEMENT May 2, 2022 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: DBV Technologies S.A., a soci?t? anonyme formed under the laws of the French Republic, having its registered office at 177-181, avenue Pierre Brossolette, 92120 Montrouge, France and registered with the registre du commerce et des soci?t?s of Nanterre under the number 441 772 522 |
|
| April 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| April 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| April 25, 2022 |
definitive proxy statement on Schedule 14A DEF 14A 1 d177648ddef14a.htm DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Com |
|
| April 14, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 1 |
|
| April 6, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| March 9, 2022 |
Montrouge, France, March 9, 2022 Exhibit 99.1 Montrouge, France, March 9, 2022 DBV Technologies Announces Filing of 2021 Annual Report on Form 10-K and 2021 Universal Registration Document DBV Technologies (Euronext: DBV ? ISIN: FR0010417345 ? Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced the filing of its Annual Report on Form 10-K for the year ended December 31, 2021, with the U.S. Secu |
